Radius Health, Inc. (NASDAQ:RDUS) is reporting third quarter financial results on Thursday 5th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, RDUS is expected to report 3Q20 loss of $ 0.21 per share from revenue of $ 78.38 million.
For the full year, analysts anticipate top line of $ 248.22 million, while looking forward to loss of $ 2.35 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 190.00 million ~ $ 220.00 million
Click Here For More Historical Outlooks Of Radius Health, Inc.
Previous Quarter Performance
Radius Health, Inc. communicated loss for the second quarter of $ 0.67 per share, from the revenue of $ 50.11 million. Wall street analysts are predicting, RDUS to report 2Q20 loss of $ 0.74 per share from revenue of $ 47.40 million. The bottom line results beat street analysts by $ 0.07 or 9.46 percent, at the same time, top line results outshined analysts by $ 2.71 million or 5.72 percent.
Stock Performance
Shares of Radius Health, Inc. traded up $ 0.51 or 3.85 percent on Wednesday, reaching $ 13.75 with volume of 568.00 thousand shares. Radius Health, Inc. has traded high as $ 14.25 and has cracked $ 13.23 on the downward trend
The closing price of $ 13.75, representing a 30.44 % increase from the 52 week low of $ 10.15 and a 47.94 % decrease over the 52 week high of $ 25.43.
The company has a market capital of $ 638.99 million and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
Conference Call
Radius Health, Inc. will be hosting a conference call at 8:30 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.radiuspharm.com
Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.
